Parameswaran Venugopal, MD | oneAMYLOIDOSISvoice
Healthcare Professionals

Parameswaran Venugopal, MD

Healthcare Professional
Professor of Medicine
The Elodia Kehm Chair of Hematology
Director, Section of Hematology
Rush University Medical Center
1653 W. Congress Parkway
Chicago, Illinois, United States
Parameswaran Venugopal is a Professor of Oncology, Associate Professor of Medicine in the Division of Hematology and Oncology at Rush University and Director of the Section of Hematology and Stem Cell Transplantation at Rush University Medical Center. He received his medical degree from University of Kerala Medical College, India followed by residency and fellowship from Rush University Medical Center. 
Dr. Venugopal is a hematology specialist with clinical expertise in areas like acute lymphoblastic leukemia (all), acute myeloid leukemia (aml), acute promyelocytic leukemia (apl), anemia, aplastic anemia, blood disorders, cancerous, blood disorders, noncancerous, bone marrow biopsy, chemotherapy, chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll), chronic myeloid leukemia (cml), chronic myelomonocytic leukemia (cmml), cutaneous t-cell lymphoma (ctcl), hairy cell leukemia, hodgkin lymphoma, leukemias – acute and chronic, multiple myeloma, myelodysplastic syndrome (mds), myeloproliferative neoplasms, non-hodgkin lymphoma, targeted therapy for hematologic cancer and thrombocytopenia.
Parameswaran Venugopal, hematologist at Rush, is among the Leukemia Research Foundation’s “Heroes for Hope.” He is a fixture of the Leukemia Research Foundation’s Patient Education Series, which includes Town Hall Meeting and a Treatment Options for Blood Cancer Patients Conference. “Dr. Venu”, as he is called by some, enjoys working with patients because he feels he is “able to do something which helps them.” 
Representative Publications:


The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.